Compare CBNK & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBNK | ALT |
|---|---|---|
| Founded | 1974 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 486.8M | 421.5M |
| IPO Year | 2018 | 2005 |
| Metric | CBNK | ALT |
|---|---|---|
| Price | $31.70 | $3.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $34.50 | $17.67 |
| AVG Volume (30 Days) | 80.3K | ★ 2.6M |
| Earning Date | 04-21-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.52% | N/A |
| EPS Growth | ★ 60.85 | 25.37 |
| EPS | ★ 3.41 | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | $16.20 | N/A |
| Revenue Next Year | $8.52 | N/A |
| P/E Ratio | $9.28 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $26.20 | $2.87 |
| 52 Week High | $36.40 | $7.73 |
| Indicator | CBNK | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 67.77 | 40.69 |
| Support Level | $30.22 | $2.89 |
| Resistance Level | $33.57 | $4.25 |
| Average True Range (ATR) | 0.81 | 0.17 |
| MACD | 0.30 | 0.05 |
| Stochastic Oscillator | 93.17 | 54.48 |
Capital Bancorp Inc is a bank holding company. The company through its holdings operates as a commercial-focused community bank that serves businesses, not-for-profit associations, and entrepreneurs throughout the region. The bank operates through four divisions including Commercial Banking, Capital Bank Home Loans, OpenSky, and Windsor Advantage. The company generates majority revenue from the Commercial bank sector. Commercial Banking division focuses on providing personalized service to commercial clients throughout the operations supplemented by lending outside primary market as well as engaging in government guaranteed lending on a national basis.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.